INTRODUCTION
============

HISTORICAL BACKGROUND
---------------------

In the field of cancer chemotherapy, it has been well documented that glutathione (GSH) plays a pivotal role in conferring cancer cells resistance to anti-tumor drugs, such as cisplatin and alkylating agents. Several lines of evidence suggest that certain multi-drug eﬄux pumps encoded by ATP-binding cassette (ABC) transporter genes are up-regulated by oxidative stress and/or chemotherapeutic agents to contribute to multi-drug resistance of cancer cells. About two decades ago, Ishikawa and Kuo first reported that many cytotoxic agents induced the expression of both γ-glutamylcysteine synthetase (γ-*GCS*) and *ABCC1 (MRP1)* genes ([@B8]; [@B14], [@B13]; [@B3]; [@B35]). Coordinated up-regulation of both γ-*GCS* and *ABCC1* genes was found in human malignant tissues. Among 32 cases of human colorectal cancer biopsies, 78% of the cases exhibited co-elevated expression of *ABCC1* and γ-*GCS* genes in tumor samples as compared with their corresponding adjacent naïve normal samples ([@B14]). At that time, it was speculated that a common transcriptional regulator might exist for the coordinated expression of both γ-*GCS* and *ABCC1* genes ([@B8]).

TRANSCRIPTION FACTOR NRF2 AS A MASTER SWITCH IN GENE EXPRESSION
---------------------------------------------------------------

During the past two decades, evidence has accumulated to show that one transcription factor named NF-E2-related factor 2 (NRF2) is a common redox regulator to control cellular adaptation/protection to external stimuli by inducing antioxidant and detoxification genes ([@B21]; [@B12]; [@B22]). In fact, NRF2 is a major player in the transcriptional upregulation of many target genes in phase II drug metabolizing enzymes and certain phase III ABC transporters (ABCC2, ABCC3, and ABCG2; [@B1]). The 5′-flanking region of many of phase II xenobiotic detoxifying genes (e.g., γ-*GCS*) contains an antioxidant response element (ARE). NRF2 directly binds to the ARE sequence in those target genes ([@B27]; [@B28]). Furthermore, it has recently been reported NRF2 mediates cancer cell proliferation and drug resistance ([@B16]; [@B4]; [@B5]; [@B32]; [@B31]; [@B33]; [@B26]).

NF-E2-related factor 2 is a "cap'n'collar" basic region-leucine zipper (CNC-bZip) transcription factor involved in the induction of ARE-regulated genes ([@B20]; [@B21]; [@B12]; [@B16]; [@B4]; [@B5]; [@B22]; [@B32]; [@B31]; [@B33]). Under non-stressed conditions, NRF2 protein is associated with Kelch-like ECH associating protein 1 (*KEAP1*; [@B11]) that negatively regulate NRF2 by retrieving the NRF2 protein in the cytoplasmic compartment. However, oxidative stress and/or electrophilic attack modifies the KEAP1 protein, which leads to dissociation of NRF2 from KEAP1. The NRF2 protein, thus released, is subsequently translocated into the nucleus. Coupling with small multiple alignment format (MAF) sequences, NRF2 binds to ARE sequences ([@B10]). Many genes encoding detoxifying and antioxidant enzymes have been found to be regulated by the NRF2 protein in this manner ([@B10]; [@B7]; [@B24]; [@B21]; [@B2]; [@B12]; [@B22]). Recent studies, on the other hand, have shown that NRF2 contributes to cancer cell proliferation, drug resistance, and metabolic re-programming, as well ([@B15]; [@B16]; [@B4]; [@B5]; [@B32]; [@B19]; [@B31]; [@B33]). In this context, the *NRF2* gene is regarded as a "double-edged sword," namely, protection of normal cells and progression of cancer malignancy.

GENETIC POLYMORPHYSMS IN THE *NRF2* GENE
========================================

[@B34] first reported three single nucleotide polymorphisms (SNPs; -653A \> G, -651G \> A, and -617C \> A) and one triplet repeat polymorphism in the regulatory region of the human *NRF2* gene. The physiological significance of these SNPs was not known at that time. Three years later, [@B17] reported the impact of those SNPs on the regulation of *NRF2* gene expression. In fact, the -617C \> A SNP significantly affected basal NRF2 protein levels *in vitro* ([@B17]). Moreover, the SNP -617C \> A was found to be associated with a higher risk of oxidant-induced acute lung injury in humans ([@B17]). These findings suggest that the SNP (-617C \> A) in the ARE-like loci of the human *NRF2* gene is important for self-induction of the *NRF2* gene ([@B23]); refer to schematic illustrations in **Figure [1](#F1){ref-type="fig"}**.

![**Schematic illustrations showing the effect of *NRF2* SNP -617C \> A and *MDM2* SNP *c.* 309 T \> G on the p53-mediated suppression of cancer cell proliferation **(A)** and ABCG2-mediated drug resistance to gefitinib **(B)**.** Refer to [@B23] for more details.](fgene-05-00383-g001){#F1}

SNP (--617C \> A) IN THE *NRF2* GENE AS A BIOMARKER FOR PROGNOSIS OF LUNG CANCER
================================================================================

NF-E2-related factor 2 plays a pivotal role in protecting normal cells from external toxic challenges and oxidative stress, whereas it can modulate the cancer phenotype (**Figure [1A](#F1){ref-type="fig"}**) and also endow cancer cells resistance to anticancer drugs (**Figure [1B](#F1){ref-type="fig"}**). NRF2 activation appears to be associated with the emergence of cancer resistance to various anticancer drugs by transcriptionally activating a battery of self-defense genes. Indeed, NRF2 can induction the expression of γ-*GCS* and *ABCC1* genes involved cancer cell resistance to cisplatin and alkylating agents ([@B8]; [@B1]). In addition, ABCG2 is known to mediate the eﬄux of gefitinib (Iressa) from cancer cells ([@B25]), and its expression is regulated by NRF2 ([@B28]) and the EGFR-tyrosine kinase cascade ([@B18]; [@B6]; **Figure [1B](#F1){ref-type="fig"}**).

Single nucleotide polymorphism -617C \> A could affect the positive feedback loop of transcriptional activation of the *NRF2* gene, and thereby it can regulate the NRF2 protein level. It is proposed that the homozygote -617A/A significantly attenuates the positive feedback loop of transcriptional activation of the *NRF2* gene. Interestingly, Asians, including Japanese, have higher frequencies of the -617A allele as compared with African--Americans and Caucasians ([@B23]). As demonstrated in **Figure [2A](#F2){ref-type="fig"}**, Japanese lung cancer patients carrying SNP homozygous alleles (*c.*-617A/A) exhibited remarkable survival over 1,700 days after surgical operation (log-rank *p* = 0.021). This SNP is considered as a new biomarker for prognosis of lung cancer in Japanese population, and a hypothetical molecular mechanism has been proposed ([@B23]).

![**Kaplan-Meier plots showing the overall survival of patients harboring the WT homozygote (-617C/C), WT/SNP heterozygote (-617C/A), or SNP homozygote (-617A/A) in the *NRF2* gene **(A)** and genotyping of *NRF2* SNP -617C \> A by the rapid SNP-detection method (B, upper panels) and DNA sequence analysis (B, lower panels).** Data from [@B23].](fgene-05-00383-g002){#F2}

SOMATIC MUTATIONS IN *NRF2* AND *KEAP1* GENES
=============================================

The genetic polymorphisms are the "intrinsic" mechanism, whereas the mutations are the "acquired" mechanism in cancer cells. Hitherto, several mutations in the *NRF2* and *KEAP1* genes have been reported in carcinomas of the lung ([@B31]), liver ([@B36]), stomach ([@B36]), and breast ([@B29]). Abnormalities in NRF2 activity were correlated with poor prognosis in terms of either recurrence-free or overall 5-year survival. Increased expression of NRF2 protein and decreased expression of KEAP1 protein were often observed as common abnormalities in non-small cell lung cancer (NSCLC), being associated with poor prognosis ([@B30]).

FUTURE PERSPECTIVES
===================

Identification and validation of biomarkers for personalized cancer therapy is one of the challenges in cancer management. To practically realize personalized medicine, development of cost-effective methods is required. Furthermore, genetic information in each patient's record should be timely provided for individualized cancer treatment. In this regards, we have recently developed a rapid isothermal method to detect genetic polymorphisms in the *NRF2* gene and correlated the genotyping data with the survival of patients who had primary lung cancer ([@B23]). By means of the new method ([@B9]), we could detect the SNP -617C \> A in the *NRF2* gene within 30 to 45 min without DNA isolation and PCR amplification (**Figure [2B](#F2){ref-type="fig"}**). Such genotyping methods would provide a simple and practical tool for personalized cancer therapy and assessment of prognosis.
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